Mepolizumab (anti-IL5)

Name: Mepolizumab (anti-IL5)
Brand: MedChemExpress
SKU: HY-P9945A
Rating: 4.5 (0 reviews)

Cat. No.: HY-P9945A Pureza: 97.50%: Ficha de datos
COA

SDS

FAQs
Technical Support

Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 196078-29-2

Tamaño	Stock	Cantidad
1 mg	En stock	Estimated Time of Arrival: December 31
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	Obtener un presupuesto
100 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Other Forms of Mepolizumab (anti-IL5):

Mepolizumab In-stock

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Interleukin Related:

Ver todas las isoformas

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

IL-5

In Vivo

Mepolizumab shows nearly linear PK after intravenous administration over a 6000-fold dose range (0.05-300 mg/kg), inhibiting eosinophil proliferation with an IC₅₀ of 1.43 mg/mL^[1].
Pharmacokinetic analysis of mepolizumab in cynomolgus monkeys^[1]

Route	Dose (mg/kg)	C_max (μg/mL)	AUC_{0-INF_obs} (μg·h/mL)	T_1/2 (days)	Cl_obs (mL·h/kg)	V_{ss_obs} (mL/kg)
i.v.	300	6700	1405000	11.7	0.217	74.6
i.v.	3	89.1	14600	11.2	0.208	82.1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gene ID

3567 [NCBI]

Accession

P05113

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Peso molecular

146.24 kDa

No. CAS

196078-29-2

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Mepolizumab (anti-IL5)]

Envío

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Immobilized IL-5 Protein, Human can bind Mepolizumab. The EC₅₀ for this effect is 118.8 ng/mL.

Pureza y Documentación

Purity: 97.50%

Select Batch:

Ficha de datos (260 KB) SDS (251 KB)

COA (232 KB) SDS-PAGE (65 KB) SEC-HPLC (122 KB)

Inhibitory Antibodies User Guide (603 KB)

Referencias

[1]. P Zia-Amirhosseini, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7. [Content Brief]

[2]. Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151. [Content Brief]

[3]. Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797. [Content Brief]